- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03269045
Study of ORL-1B in Patients With Biotinidase Deficiency
January 13, 2018 updated by: Orpha Labs
An Open-label, Single-arm, Phase 2 Study of ORL-1B in Patients With Biotinidase Deficiency
An Open-label, Single-arm, Phase 2 Study of Biotin in Patients With Biotinidase Deficiency.
Study Overview
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Phase 2
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
No older than 18 years (ADULT, CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Diagnosis of biotinidase deficiency.
- Less than 18 years old.
Exclusion Criteria:
- Diagnosis of any other disease that is not a manifestation of biotinidase deficiency.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: Treatment with ORL-1B.
Pediatric patients with biotinidase deficiency.
|
Oral ORL-1B
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement in seizure frequency
Time Frame: 12 months
|
Statistically significant improvement in seizure frequency after the ORL-1B treatment.
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
August 31, 2013
Primary Completion (ACTUAL)
January 1, 2018
Study Completion (ACTUAL)
January 1, 2018
Study Registration Dates
First Submitted
August 28, 2017
First Submitted That Met QC Criteria
August 29, 2017
First Posted (ACTUAL)
August 31, 2017
Study Record Updates
Last Update Posted (ACTUAL)
January 17, 2018
Last Update Submitted That Met QC Criteria
January 13, 2018
Last Verified
January 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Biot-1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Biotinidase Deficiency
-
Fondation Ophtalmologique Adolphe de RothschildCompleted
-
West Kazakhstan Medical UniversityRecruitingOrnithine Transcarbamylase Deficiency | Biotinidase Deficiency | Citrullinemia | Glutaric Acidemia Type II | Argininosuccinic Aciduria | Maple Syrup Urine Disease | Primary Carnitine Deficiency | Homocystinuria | Carnitine Palmitoyltransferase II Deficiency | Arginase Deficiency | Very Long-chain Acyl-CoA... and other conditionsKazakhstan
-
Nutrition Institute, SloveniaEuropean Regional Development Fund; Vizera d.o.o.; Frutarom Etol d.o.o.CompletedVitamin B 12 Deficiency | Vitamin d Deficiency | Protein DeficiencySlovenia
-
Washington University School of MedicineUniversity of California, Davis; Universidad San Francisco de Quito; Pan American...CompletedCholine Deficiency | Vitamin B-12 Deficiency | Lipids Deficiency | Amino Acids DeficiencyEcuador
-
Texas A&M UniversityUnknownCognitive Change | Nutritional Anemia | Diet, Healthy | Nutrient Deficiency | Diet; Deficiency | Visual Spatial Processing | Dietary Deficiency | Dietary B12 Deficiency | Dietary Zinc Deficiency | Dietary Vitamin B12 Deficiency Anemia | Dietary Deficiency of Selenium and Vitamin EUnited States
-
SourseCitruslabsActive, not recruitingMood | Energy Supply; Deficiency | B12 Deficiency VitaminUnited States
-
University of California, DavisUniversity of California, San Francisco; University of Rhode Island; Ethiopian... and other collaboratorsNot yet recruitingVitamin B 12 Deficiency | Folate Deficiency | Iodine Deficiency | Anemia Deficiency | Salt Intake | Anemia Macrocytic
-
ProofPilotJoovvUnknownTestosterone Deficiency | Estrogen DeficiencyUnited States
-
Meir Medical CenterCompletedFolic Acid Deficiency | Vitamin B12 DeficiencyIsrael
Clinical Trials on ORL-1B
-
Orpha LabsUnknownGlycogen Storage Disease, Type 14Turkey
-
Seno Medical Instruments Inc.SuspendedBreast CancerUnited States
-
Benitec Biopharma, Inc.RecruitingOculopharyngeal Muscular DystrophyUnited States
-
Boryung Pharmaceutical Co., LtdCompletedEssential Hypertension | Primary HypercholesterolemiaKorea, Republic of
-
S. Andrea HospitalItalian Multiple Sclerosis FoundationCompleted
-
National Cancer Institute (NCI)CompletedRecurrent Mycosis Fungoides and Sezary Syndrome | Refractory Mycosis Fungoides and Sezary Syndrome | Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7 | Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7 | Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7 | Stage IIIA Mycosis... and other conditionsUnited States
-
Children's Hospital of PhiladelphiaFriedreich's Ataxia Research Alliance; Vidara Therapeutics Research LtdCompleted
-
Nantes University HospitalActive, not recruiting
-
Merck KGaA, Darmstadt, GermanyMerck B.V., NetherlandsTerminated